Drug Shortage Crisis: What Happens When Generic Manufacturers 'Just Say No'

48 Pages Posted: 13 May 2016

See all articles by Stacey B. Lee

Stacey B. Lee

Johns Hopkins University - Carey Business School; Johns Hopkins University - Bloomberg School of Public Health

Date Written: May 13, 2014

Abstract

Jenny Morrill, a mother and former arts administrator, has been battling ovarian cancer since 2007. When she recently went to her scheduled chemotherapy treatment, the hospital presented her with both good and bad news. The good news was that she was responding well to the prescribed chemotherapy drug, Doxil. The bad news was that due to nationwide shortages, the hospital had no more Doxil to give her. Ms. Morrill said her “jaw dropped.” In describing her health predicament, Ms. Morrill said, A lot of things can go wrong when you’re in cancer treatment — your white count can go down, you can become too frail to get treatment, the chemo can stop working. One of the things you never consider is that treatment might just not be available. It’s like you’re out in the ocean and the guy on the lifeboat says, “Sorry, they ran out of life rings.”

Keywords: Drug Shortage, Generic Manufacturers, FDA

Suggested Citation

Lee, Stacey B., Drug Shortage Crisis: What Happens When Generic Manufacturers 'Just Say No' (May 13, 2014). Oregon Law Review, Vol. 93, 2014, Available at SSRN: https://ssrn.com/abstract=2779605

Stacey B. Lee (Contact Author)

Johns Hopkins University - Carey Business School ( email )

100 International Drive
Baltimore, MD 21202
United States

Johns Hopkins University - Bloomberg School of Public Health ( email )

615 North Wolfe Street
Baltimore, MD 21205
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
30
Abstract Views
316
PlumX Metrics